First-in-class drug-Fc conjugate shows efficacy in preclinical cancer models

Nov. 8, 2023

CD73 (NT5E) contributes to cancer cell proliferation, migration and tumor angiogenesis by limiting immune response in the tumor microenvironment.

BioWorld Science Conferences Society for Immunotherapy of Cancer Cancer Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for May 26, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 26, 2026

Microscopy of a cross-section of mouse skin containing melanoma tumors

Researchers identify innate immune barrier against melanoma

BioWorld

Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...

In the clinic for May 26, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...

Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers

BioWorld Science

Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...